Mirum Pharmaceuticals To Showcase LIVMARLI Data From Its ALGS And PFIC Programs At The NASPGHAN Annual Meeting
Mirum Pharmaceuticals To Showcase LIVMARLI Data From Its ALGS And PFIC Programs At The NASPGHAN Annual Meeting
mirum pharmaceuticals将在NASPGHAN年会上展示其ALGS和PFIC项目的LIVMARLI数据
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced its participation in the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) annual meeting taking place November 6-9, 2024, in Hollywood, Florida. Data highlighting clinical benefit and real-world evidence for patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC), treated with LIVMARLI (maralixibat) oral solution, will be presented during the meeting.
Mirum Pharmaceuticals公司（纳斯达克股票代码：MIRM）今天宣布将参加2024年11月6日至9日在佛罗里达好莱坞举行的北美儿科肠胃肝营养学会（NASPGHAN）年会。届时将介绍使用LIVMARLI（maralixibat）口服溶液治疗ALGS（阿拉吉尔综合征）和PFIC（进行性家族性肝内胆汁淤积症）患者的临床益处和现实证据的数据。
资讯热榜
更新时间